An interventional study of Fish oil enteral supplementation and Fish oil oral supplementation in Lung Cancer and Surgery, sponsored by National Institute of Respiratory Diseases, Mexico. Suspended at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by National Institute of Respiratory Diseases, Mexico · Not applicable, Interventional, and Prevention
The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Lung Neoplasms with a site in Mexico — 14 open to participants now, 21 under way, 13 of them phase 3. Lung Neoplasms · Mexico.
Among the 52 studies in Lung Neoplasms with a site in Mexico, this one is the 28th largest by planned enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 with no phase, and was the 44th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →14 of the 52 studies in Lung Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Mexico, United States, Argentina and 31 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in Mexico, United States, Argentina and 21 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Mexico, United States, Argentina and 22 more countries
Ages 18+
Hoffmann-La Roche · Sites in Mexico, United States, Argentina and 25 more countries
Ages 18+
GlaxoSmithKline · Sites in Mexico, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 30 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 310 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 430 across the 40 interventional studies, 741 across the 12 observational. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 52 have an industry lead sponsor. The 10 most frequent:
National Institute of Respiratory Diseases, Mexico is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
National Institute of Respiratory Diseases, Mexico has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Lung Neoplasms with a site in Mexico that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT07099898Phase 3GlaxoSmithKlineA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | 2027-11-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 52 studies in Lung Neoplasms with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to analyze the effect of enriched formula with omega-3 in the 30-day incidence infection and inflammatory response following lung resection surgery in lung cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer enriched enteral formula
Dietary Supplement: Fish oil enteral supplementation
Patients admitted one day before surgery. Home-self administration of enriched enteral formula three days before surgery
Dietary Supplement: Fish oil oral supplementation
Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer standard enteral formula
Dietary Supplement: Enteral nutrition without fish oil
Patients admitted one day before surgery. Home-self administration of standard enteral formula three days before surgery
Dietary Supplement: Oral nutritional supplement without fish oil
Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
30-day incidence infection
Incidence of infectious complications after surgery diagnosed using any of these criteria: Infection of surgery wound confirmed by culture Infection confirmed by blood culture Pneumonia developed after surgery confirmed by chest x Ray.
Time frame: 30-day incidence infection following lung resection in lung cancer patients.
Changes in prostaglandin E2
Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).
Time frame: At the beginning of nutritional therapy and at day-4 following surgery
Changes in Interleukin-6
Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).
Time frame: At the beginning of nutritional therapy and at day-4 following surgery
Changes in Tumor Necrosis Factor Alpha (TNF-α)
Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).
Time frame: At the beginning of nutritional therapy and at day-4 following surgery
Number of participants with therapeutic antibiotics prescription
Frequency of therapeutic antibiotics prescription will be collected from medical records and medication administration registers.
Time frame: During the hospital stay until 30-day
Hospital lenght of stay
Number of calendar days that elapsed since hospital admission to the day of hospital discharge
Time frame: During the hospital stay until 90-day
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Respiratory Diseases, Mexico